Bosulif better than competitor as first-line treatment in rare leukemia, study finds

6 December 2016
pfizer-logo-big

Bosulif (bosutinib) has shown superiority over a competitor as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in a Phase III trial.

US pharma giant Pfizer (NYSE: PFE) and its partner, UK-based drug development company Avillion, announced that the BFORE study, which compared Bosulif with imatinib, a drug sold by Switzerland’s Novartis (NOVN: VX) under the name Gleevec, had met its primary endpoint of major molecular response (MMR) at 12 months.

"This is good news for CML patients because additional first-line treatment options allow physicians to tailor therapy based on individual patient considerations"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical